Moderna’s Stock Plummets Amid COVID-19 Concerns and Market Volatility
Moderna’s stock price plummeted 7.9% after a downgraded price target raised concerns about the company’s ability to adapt to the evolving COVID-19 pandemic.
2 minutes to read
Moderna’s Stock Plummets: Investors Debate Future Prospects Amid Financial Uncertainty
Moderna’s stock has plummeted to a four-year low, leaving investors uncertain about the company’s future prospects and sparking a heated debate about its potential for a turnaround.
2 minutes to read
Moderna Faces Investor Uncertainty Amidst Market Challenges and Takeover Speculation
Moderna’s stock has plummeted over the past year, with investors facing significant losses, and a takeover is being considered as a potential exit strategy to unlock value from the company’s mRNA pipeline.
2 minutes to read
Moderna Faces Revenue and EPS Decline Ahead of Earnings Release Amid Takeover Speculation
Moderna is set to release its quarterly earnings on February 14, 2025, with analysts predicting a decline in revenue and earnings per share due to waning vaccine demand and market fatigue.
One minute to read